Olivia Seeber
Features and Long-Term Outcomes of Stage IV Melanoma Patients Achieving Complete Response Under Anti-PD-1-Based Immunotherapy.
Chatziioannou E, Leiter U, Thomas I, Keim U, Seeber O, Meiwes A, Boessenecker I, Gonzalez S, Torres F, Niessner H, Sinnberg T, Forschner A, Flatz L, Amaral T. Features and Long-Term Outcomes of Stage IV Melanoma Patients Achieving Complete Response Under Anti-PD-1-Based Immunotherapy. Am J Clin Dermatol 2023; 24:453-467.
04.05.2023Features and Long-Term Outcomes of Stage IV Melanoma Patients Achieving Complete Response Under Anti-PD-1-Based Immunotherapy.
04.05.2023Am J Clin Dermatol 2023; 24:453-467
Chatziioannou Eftychia, Leiter Ulrike, Thomas Ioannis, Keim Ulrike, Seeber Olivia, Meiwes Andreas, Boessenecker Isabell, Gonzalez Stephanie Sanchez, Torres Francisco Merraz, Niessner Heike, Sinnberg Tobias, Forschner Andrea, Flatz Lukas, Amaral Teresa
Association between Immune-Related Adverse Events and Survival in 319 Stage IV Melanoma Patients Treated with PD-1-Based Immunotherapy: An Approach Based on Clinical Chemistry
Serna-Higuita L, Eigentler T, Garbe C, Thomas I, Seeber O, Flatz L, Leiter U, Forschner A, Amaral T, Martus P. Association between Immune-Related Adverse Events and Survival in 319 Stage IV Melanoma Patients Treated with PD-1-Based Immunotherapy: An Approach Based on Clinical Chemistry. Cancers (Basel) 2021; 13
06.12.2021Association between Immune-Related Adverse Events and Survival in 319 Stage IV Melanoma Patients Treated with PD-1-Based Immunotherapy: An Approach Based on Clinical Chemistry
06.12.2021Cancers (Basel) 2021; 13
Serna-Higuita Lina María, Eigentler Thomas Kurt, Garbe Claus, Thomas Ioannis, Seeber Olivia, Flatz Lukas, Leiter Ulrike, Forschner Andrea, Amaral Teresa, Martus Peter